Accession Number : ADA554551


Title :   Targeting MRS-Defined Dominant Intraprostatic Lesions with Inverse-Planned High Dose Rate Brachytherapy


Descriptive Note : Final addendum 26 May 2009-25 May 2010


Corporate Author : CALIFORNIA UNIV SAN FRANCISCO


Personal Author(s) : Pouliot, Jean ; Hsu, I-Chow ; Kurhanewicz, John ; Noworelski, Sue


Full Text : http://www.dtic.mil/get-tr-doc/pdf?AD=ADA554551


Report Date : Jun 2010


Pagination or Media Count : 20


Abstract : A combination of MRI/MRSI is used to define the distribution of Dominant Intraprostatic Lesions (DIL) within the prostate. This information is used to perform dose escalation of the DIL without compromising the dose coverage of the prostate and the protection to the urethra, rectum, and bladder for prostate cancer patients treated with High Dose Rate (HDR) brachytherapy. The multi-image fusion process has been presented at national meetings during this period. The steps and criteria involved in the series of image fusions and in the planning and verification of the dose delivery process are presented. Information from one image data set to another in the series of MRS MRI CT CBCT can be accurately transferred and used for the planning and verification of the dose delivery during prostate HDR brachytherapy. Final CHR approval was obtained in 2008 and patient enrollment has begun. So far, 10 patients were treated with HDR brachytherapy with a DIL boost level ranging from 0 to 30%, using the previously established class solution for the set of parameters used by the inverse planning in order to boost the dominant intra-prostatic lesion (DIL) defined by MRI/MRSI. The DIL dose was significantly increased without any violation of standard dosimetric index requirements.


Descriptors :   *PROSTATE CANCER , BLADDERS , DATA BASES , DOSAGE , DOSE RATE , HOSPITALIZATIONS , PATIENTS , PROSTATE GLAND , SYMPOSIA , TARGETING , URINARY SYSTEM


Subject Categories : Anatomy and Physiology
      Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE